Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Galapagos 200 euro per aandeel
Volgen
inspirator schreef op 18 april 2018 22:53 :
FDA panel geeft as maandag scores weer van Filgotinib vwb Arthritis.
Met 99% zekerheid dat koers Galapagos volgende week boven 100 euro staat.
Gilead Sciences Inc. and Galapagos NV may also reflect read-through to their experimental filgotinib treatment, with upside for Galapagos shares of 5 percent and downside risk of 10 percent, Credit Suisse estimates.
www.bloomberg.com/news/articles/2018-... dus 5% up als er wat goed nieuws is en mocht het tegenvallen dan een down van 10% vind ik toch niet zo leuk om te lezen dus wachten maar af op .........
Onno vd Stolpe heeft vakantiedagen van 2018 al op. Kan hij weer als vanouds Galapagos representeren. Of Gilead het leuk vindt of niet.
Als de koersen vandaag en morgen flink gaan oplopen weten wij de uitslag voor maandag al en die is echt wel meer dan 5% up
Concurrent van Filgotinib valt door de mand. Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. LLY, -0.83% and Incyte Corp. INCY,
Krijgt Onno nog gelijk. It is just the beginning. FDA staff raises safety concerns over Lilly/Incyte arthritis drug This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts. kfgo.com/news/articles/2018/apr/19/fd...
Wel balen als overnamebod van Gilead op Galapagos komt voor opening beurs morgenvroeg.
inspirator schreef op 19 april 2018 20:48 :
Wel balen als overnamebod van Gilead op Galapagos komt voor opening beurs morgenvroeg.
hahahahah gaat ech nie gebeuren
inspirator schreef op 19 april 2018 20:45 :
Krijgt Onno nog gelijk.
It is just the beginning.
FDA staff raises safety concerns over Lilly/Incyte arthritis drug
This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts.
kfgo.com/news/articles/2018/apr/19/fd...
Concurrentie van Galapagos krijgt klap en met laatste persbericht wordt bevestigd dat produkten van Galapagos blockbusters zijn. Hiedoor is kans op overnamebid op korte termijn erg groot. Koers Galapagos gaat morgen naar all time high en klimt dan richting 200 euro. Galapagos creates new warrant plan 19 April 2018 at 22:01 CET Mechelen, Belgium; 19 April 2018, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 1,585,000 warrants under new warrant plans for the benefit of employees, future employees, directors and a consultant of the company and its subsidiaries. On 19 April 2018, the board of directors of Galapagos approved the "Warrant Plan 2018", a warrant plan intended mainly for certain (future) employees of the company and its subsidiaries, and also for directors and an independent consultant of the company, and the "Warrant Plan 2018 RMV," a warrant plan intended for certain employees of its French subsidiary, Galapagos SASU, within the framework of the authorized capital. Under these warrant plans, 1,585,000 warrants were created, subject to acceptances, and offered to the beneficiaries of the plans. The offer of warrants to directors remains subject to approval of the annual shareholders' meeting to be held on 24 April 2018. The warrants have an exercise term of eight years as of the date of the offer and have an exercise price of €79.88 (the average closing price of the share on Euronext Amsterdam and Brussels during the thirty days preceding the date of the offer). The warrants are not transferable and can in principle not be exercised prior to 1 January 2022. Each warrant gives the right to subscribe to one new Galapagos share. Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The warrants as such will not be listed on any stock market. Galapagos' total share capital currently amounts to €277,122,928.92; the total number of securities conferring voting rights is 51,234,962, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,660,623, which equals the total number of voting rights that may result from the exercise of these warrants, and excludes the 1,585,000 warrants of Warrant Plan 2018 and Warrant Plan 2018 RMV, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
inspirator schreef op 19 april 2018 20:45 :
Krijgt Onno nog gelijk.
It is just the beginning.
FDA staff raises safety concerns over Lilly/Incyte arthritis drug
This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts.
kfgo.com/news/articles/2018/apr/19/fd...
Concurrent van Filgotinb vwb Arthritis is knockout. Dit gaat koers van Galapagos weer naar 100 euro leiden,
De optieexpiratie vandaag, houdt de bal nog effe onder water. Koers Galapagos staat op knallen.
inspirator schreef op 20 april 2018 09:58 :
De optieexpiratie vandaag, houdt de bal nog effe onder water.
Koers Galapagos staat op knallen.
Expiratie achter de rug...... koers Galapagos mag weer omhoog. Op naar 1ste koers doel Galapagos > 100 euro.
20 programs to enter clinic or preclinical development. Gilead knows that some molecules could make a future shift in IBD-treatment, or could lead to dual cominations with Filgotinib. Filgotinib in 10 indications (RA, Crohn, UC, PsA, AS, Lupus, Uveitis, JIA, Sjogren and CGvHD). Gilead in-licensed this molecule, but will have to pay $1.2 billion development/regulatory... milestones and 20-30% royalties to Galapagos by further success (Big 5 EU and Benelux profit split!). Galapagos is very interesting for Gilead. The pipeline is expanding rapidly and they have multiple Disease Modifying Targets which has proven itself in patients. If there will be a takeover..? The Board of Galapagos doesn't want a takeover. They have ambitions for themselves. They also seek a strategic partnership with Big Pharma, so Gilead is faced with another strategic stakeholder. Maybe Gilead will respect this independancy of Galapagos in favor of first right negotiations or other privileges...
CEO van Galapagos Onno van de Stolpe zei dat hij zich kan voorstellen dat Gilead interesse heeft, maar dat aandeelhouders uiteindelijk beslissen of een overname interessant is.
inspirator schreef op 24 april 2018 23:15 :
Notulen van AVA 24-4-2018
www.glpg.com/docs/view/5adf4bc426082-nl Op de AVA waren gisteren 26,7 miljoen aandelen Galapagos vertegenwoordigd. De grote jongens Citi 7,3 miljoen Gilead 7,3 miljoen BNP 6,1 miljoen Deutsche Bank 3,9 miljoen Verleenden alle volmacht voor goedkeuring van voorstellen aan Galapagos. Deze jongens weten meer en regisseren overname van Galapagos. Vergoeding voor bestuur is lucratief warrantplan. Jammer dat Onno vd Stolpe instemt met een schamel overnamebod op aandelen Galapagos.
inspirator schreef op 25 april 2018 08:29 :
[...]
Op de AVA waren gisteren 26,7 miljoen aandelen Galapagos vertegenwoordigd.
De grote jongens
Citi 7,3 miljoen
Gilead 7,3 miljoen
BNP 6,1 miljoen
Deutsche Bank 3,9 miljoen
Verleenden alle volmacht voor goedkeuring van voorstellen aan Galapagos.
Deze jongens weten meer en regisseren overname van Galapagos.
Vergoeding voor bestuur is lucratief warrantplan.
Jammer dat Onno vd Stolpe instemt met een schamel overnamebod op aandelen Galapagos.
Opgeruimd staat netjes. Laat dit net de banken zijn die vandaag de stoplossen hebben getriggerd op de turbo’s en boosters. Anders gaat het de banken geld kosten als overnamebod morgen komt. Banken zijn alleen van het incasseren.
Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs. Dat is mooi, want we zitten immers inmiddels in kwartaal 2. Dus nog binnen 65 dagen meer Galapagos nieuws.
inspirator schreef op 25 april 2018 22:24 :
Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs.
Dat is mooi, want we zitten immers inmiddels in kwartaal 2.
Dus nog binnen 65 dagen meer Galapagos nieuws.
Letter from the management Dear shareholders, We reported another quarter of solid pipeline progress in the first quarter of 2018, as we prepared for the next wave of late stage studies, finished up execution on several other patient studies, and moved our early pipeline forward. In our osteoarthritis, atopic dermatitis, and cystic fibrosis programs, we are preparing for the next patient studies in the second quarter. Importantly, we received feedback from regulatory authorities for our ISABELA global pivotal studies with GLPG1690 in idiopathic pulmonary fibrosis, expected to start in the second half of 2018. We await the next round of filgotinib clinical study results, starting with the EQUATOR studies in psoriatic arthritis in the second quarter. Onno van de Stolpe, CEO of Galapagos (photo) The coming year will be data-rich, as we expect the first Phase 3 data with filgotinib in rheumatoid arthritis, along with an interim decision to move to Phase 3 in the ulcerative colitis trial and readouts in our trials in ankylosing spondylitis and psoriatic arthritis. In cystic fibrosis, we will see topline results from the PELICAN trial and a first interim readout with FALCON, a patient study of our first triple combination therapy. We expect to launch pivotal trials with GLPG1690 in IPF, building our fully proprietary IPF franchise. And with our planned start of Phase 2 studies for GLPG1205, GLPG1972, MOR106, and a second CF triple combination, we set the foundations for the next set of clinical results. Meanwhile, we continue to expand our organization to be able to execute the increasing number of clinical studies and to be ready for the anticipated market introduction of our drug candidates. Galapagos ended the first quarter of 2018 with a strong balance sheet. We are continuing to grow our late stage development organization to execute on our successful programs. The Galapagos share of proprietary late stage development is growing, leading to increased costs for our company. During 2018 we expect to be running 13 Phase 2 studies. All this will contribute to our financial guidance for operational cash burn between €220 and €240 million for full year 2018.
inspirator schreef op 25 april 2018 22:24 :
Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs.
Dat is mooi, want we zitten immers inmiddels in kwartaal 2.
Dus nog binnen 65 dagen meer Galapagos nieuws.
Deze keer gaat Onno zijn belofte niet breken. Nog maximaal 64 dagen te gaan voor goede nieuws.
inspirator schreef op 26 april 2018 19:01 :
[...]
Deze keer gaat Onno zijn belofte niet breken.
Nog maximaal 64 dagen te gaan voor goede nieuws.
Kijk zo kennen we Onno weer. Nog geen dag later, en er is al goed nieuws. Onno chapeau.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)